ReviewFrontiers in immunology2021
Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Human Immune Response to Influenza Neuraminidase After Vaccination: A Systematic Review.Influenza and other respiratory viruses · 2025Pooled it
- A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses.Journal of virology · 2026Article
- Article
- Pre-existing and cross-reactive immunity to avian influenza H5N1 in humans: Implications for pandemic risk and vaccine strategies.The Journal of infection · 2026Review
- Rapid Detection of N9 Subtype Avian Influenza Viruses Using an NA-Targeting Lateral Flow Immunoassay.Viruses · 2026Article
- Article
- A VSV-vector vaccine simultaneously targeting H5N1 hemagglutinin and matrix protein 2 induces robust neutralizing and ADCC antibody responses and provides full protection against lethal H5N1 infection in a mouse model.Journal of virology · 2026Article
- mRNA Vaccines for Influenza: Hope for a Universal Vaccine?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection.Influenza and other respiratory viruses · 2026Article
- Hemagglutination inhibition and alternate serologic responses following Influenza A(H3N2) virus infection.medRxiv : the preprint server for health sciences · 2026Article
- Meeting Report: Fourth Correlates of Protection for Next Generation Influenza Vaccines.Influenza and other respiratory viruses · 2026Article
- Oseltamivir aziridines are potent influenza neuraminidase inhibitors and imaging agents.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Non-propagating RNA virus-vectored HA/NA vaccine prevents shedding of antigen-drifted H1N1 influenza virus in pigs.NPJ vaccines · 2026Article
- Improved cross-protection and immunity against influenza A virus in mice using a novel mRNA vaccine with optimized design of RNA sequence.Molecular therapy. Nucleic acids · 2026Article
- A nanoemulsion-adjuvanted trivalent neuraminidase vaccine confers cross-protection against divergent influenza viruses.Frontiers in cellular and infection microbiology · 2026Article
- Structural analysis of antigenic variation and adaptive evolution of the H5N1 neuraminidase gene.PLoS computational biology · 2026Article
- Comparative progress on the mechanisms of airway mucosal injury induced by different pathogens: SARS-CoV-2, influenza A virus, and Mycoplasma pneumoniae.Frontiers in cellular and infection microbiology · 2026Review
- Cross-protective efficacy of NA-based mRNA vaccine candidates against seasonal and avian influenza viruses.Frontiers in microbiology · 2026Article
- Article
- A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active site.The Journal of clinical investigation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuraminidase of influenza A and B viruses plays a critical role in the virus life cycle and is an important target of the host immune system. Here, we highlight the current understanding of influenza neuraminidase structure, function, antigenicity, immunogenicity, and immune protective potential. Neuraminidase inhibiting antibodies have been recognized as correlates of protection against disease caused by natural or experimental influenza A virus infection in humans. In the past years, we have witnessed an increasing interest in the use of influenza neuraminidase to improve the protective potential of currently used influenza vaccines. A number of well-characterized influenza neuraminidase-specific monoclonal antibodies have been described recently, most of which can protect in experimental challenge models by inhibiting the neuraminidase activity or by Fc receptor-dependent mechanisms. The relative instability of the neuraminidase poses a challenge for protein-based antigen design. We critically review the different solutions that have been proposed to solve this problem, ranging from the inclusion of stabilizing heterologous tetramerizing zippers to the introduction of inter-protomer stabilizing mutations. Computationally engineered neuraminidase antigens have been generated that offer broad, within subtype protection in animal challenge models. We also provide an overview of modern vaccine technology platforms that are compatible with the induction of robust neuraminidase-specific immune responses. In the near future, we will likely see the implementation of influenza vaccines that confront the influenza virus with a double punch: targeting both the hemagglutinin and the neuraminidase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.